I te 9 o Mei, 2025, i panuitia e Hansoh Pharmaceutical kua whakaaetia he tohu hou mō Ameile (papa almonertinib mesylate) hei hokohoko. Ko te tohu hou he maimoatanga tāpiri mō ngā tūroro pakeke e pangia ana e te mate pukupuku pūkahukahu kore-pūtau iti (NSCLC) he rerekētanga o te epidermal growth factor receptor (EGFR) exon 19 mukunga, exon 21 (L858R) rānei ō rātou pukupuku, ā, kua tangohia te pukupuku. E whā ngā tohu kua whakaaetia e Ameile i Haina, e mau tonu ana tōna tūranga rangatira i roto i ngā EGFR-TKI o te whakatupuranga tuatoru kua whakawhanakehia i roto i te motu.
Ko te pūtake o tēnei whakaaetanga ko te rangahau ARTS (HS-10296-302), he whakamātautau haumanu Wāhanga III matapōkere, matapo-rua, whakahaeretia, maha-pokapū. I tukuna ngā hua o te rangahau hei pūrongo ā-waha i te Hui-ā-Tau a te American Association for Cancer Research (AACR) 2025.
I whakaūtia e ngā raraunga mai i te rangahau ARTS i whakaaturia i te Hui-ā-Tau a te AACR 2025, mō ngā tūroro kua tangohia katoatia te NSCLC wāhanga II–IIIB EGFR-mutant, ka taea e te maimoatanga tāpiri me te Ameile—mēnā e tika ana—te whakapai ake i te oranga kore mate (DFS). I eke te reiti DFS 2-tau ki te 90.2%, me te HR o te 0.17, ā, he pai te whakahaere i te kōtaha haumaru whānui. He mea nui, i whakaurua e te rangahau ngā tūroro Hainamana anake, e whakaatu ana i te whai huatanga nui me te kōtaha haumaru whakahaere o te EGFR-TKI i whakawhanakehia i roto i te taupori Hainamana.
Mō Ameile
Hei te tuatahi o ngā EGFR-TKI o te whakatupuranga tuatoru o Haina, he pai te ngota ngota o Ameile (Aumolertinib Mesilate Tablets) me te pumau, e āhei ai te uru pai ake ki te arai toto-roro me te iti o te auau o ngā urupare kino. I tēnei wā, kua whakaaetia a Ameile mō ngā tohu e whā: te maimoatanga raina tuarua o ngā tūroro he NSCLC kua horapa, kua horapa rānei me te whakarerekētanga T790M, kua ahu whakamua i runga i te rongoā EGFR-TKI, i muri rānei i te rongoā; te maimoatanga raina tuatahi mō ngā tūroro pakeke he NSCLC kua horapa, kua horapa rānei, ā, ko ō rātou pukupuku he mukunga EGFR exon 19, he pai rānei te whakarerekētanga whakakapinga exon 21 (L858R); te maimoatanga o ngā tūroro he mate pukupuku pūkahukahu kore-pūtau iti (Wāhanga III) kua horapa, kāore e taea te tango (NSCLC) kāore anō kia ahu whakamua te mate i muri i te chemoradiotherapy platinum-based whakamutunga ko ō rātou pukupuku he mukunga exon 19 epidermal growth factor receptor ("EGFR"), he whakarerekētanga whakakapinga exon 21 (L858R) rānei; te maimoatanga tāpiri mō ngā tūroro pakeke he mate pukupuku pūkahukahu ehara i te pūtau iti (NSCLC) nō rātou ngā pukupuku he mukunga epidermal growth factor receptor (EGFR) exon 19, he whakarerekētanga exon 21 (L858R) rānei, ā, kua tangohia te pukupuku.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Wā tuku: Mei-13-2025